# LianBio: financial statements, quarterly

LIANY · OTC · CIK 1831283 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/liany.md) · [Financials](/companies/liany/financials.md) · [Filings](/companies/liany/filings.md) · [Insiders](/companies/liany/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/liany/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2020-12-31) | period not labelled (2021-03-31) | period not labelled (2021-06-30) | Q3 FY2021 (2021-09-30) | Q4 FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [2.7 d](/filings/0001831283-22-000014.md) | [53.4](/filings/0001831283-22-000042.md) | [93.0](/filings/0001831283-22-000061.md) | [4.7](/filings/0001831283-22-000075.md) | [7.7 d](/filings/0001831283-23-000041.md) | [12.3](/filings/0001831283-23-000081.md) | [28.6](/filings/0001831283-23-000110.md) | [8.3](/filings/0001831283-23-000126.md) | [10.6 d](/filings/0001831283-23-000041.md) | [10.8](/filings/0001831283-23-000081.md) | [9.5](/filings/0001831283-23-000110.md) | [9.0](/filings/0001831283-23-000126.md) |
| Operating income | $m | [(9.2) d](/filings/0001831283-22-000014.md) | [(60.5)](/filings/0001831283-22-000042.md) | [(99.5)](/filings/0001831283-22-000061.md) | [(13.5)](/filings/0001831283-22-000075.md) | [(22.0) d](/filings/0001831283-23-000041.md) | [(28.4)](/filings/0001831283-23-000081.md) | [(43.1)](/filings/0001831283-23-000110.md) | [(24.5)](/filings/0001831283-23-000126.md) | [(29.2) d](/filings/0001831283-23-000041.md) | [(26.0)](/filings/0001831283-23-000081.md) | [(25.0)](/filings/0001831283-23-000110.md) | [(26.3)](/filings/0001831283-23-000126.md) |
| Income tax | $m | [0.0 d](/filings/0001831283-22-000014.md) | [1.0](/filings/0001831283-22-000042.md) | [1.0](/filings/0001831283-22-000061.md) | [(0.4)](/filings/0001831283-22-000075.md) | [(1.0) d](/filings/0001831283-23-000041.md) | [0.0](/filings/0001831283-23-000081.md) | [0.0](/filings/0001831283-23-000110.md) | [0.0](/filings/0001831283-23-000126.md) | [(0.4) d](/filings/0001831283-23-000041.md) | [0.4](/filings/0001831283-23-000081.md) | [0.2](/filings/0001831283-23-000110.md) | [0.6](/filings/0001831283-23-000126.md) |
| Net income | $m | [(12.7) d](/filings/0001831283-22-000014.md) | [(61.6)](/filings/0001831283-22-000075.md) | [(100)](/filings/0001831283-22-000075.md) | [(13.1)](/filings/0001831283-22-000075.md) | [(21.2) d](/filings/0001831283-23-000041.md) | [(27.7)](/filings/0001831283-23-000126.md) | [(42.4)](/filings/0001831283-23-000126.md) | [(21.9)](/filings/0001831283-23-000126.md) | [(18.3) d](/filings/0001831283-23-000041.md) | [(24.0)](/filings/0001831283-23-000126.md) | [(21.6)](/filings/0001831283-23-000126.md) | [(24.0)](/filings/0001831283-23-000126.md) |
| Diluted EPS | $ per share | not reported | [(3.01)](/filings/0001831283-22-000042.md) | [(4.90)](/filings/0001831283-22-000061.md) | [(0.63)](/filings/0001831283-22-000075.md) | not reported | [(0.26)](/filings/0001831283-23-000081.md) | [(0.39)](/filings/0001831283-23-000110.md) | [(0.20)](/filings/0001831283-23-000126.md) | not reported | [(0.22)](/filings/0001831283-23-000081.md) | [(0.20)](/filings/0001831283-23-000110.md) | [(0.22)](/filings/0001831283-23-000126.md) |
| Basic EPS | $ per share | not reported | [(3.01)](/filings/0001831283-22-000042.md) | [(4.90)](/filings/0001831283-22-000061.md) | [(0.63)](/filings/0001831283-22-000075.md) | not reported | [(0.26)](/filings/0001831283-23-000081.md) | [(0.39)](/filings/0001831283-23-000110.md) | [(0.20)](/filings/0001831283-23-000126.md) | not reported | [(0.22)](/filings/0001831283-23-000081.md) | [(0.20)](/filings/0001831283-23-000110.md) | [(0.22)](/filings/0001831283-23-000126.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2020-12-31) | period not labelled (2021-03-31) | period not labelled (2021-06-30) | Q3 FY2021 (2021-09-30) | FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [254](/filings/0001831283-22-000014.md) | [235](/filings/0001831283-22-000042.md) | [143](/filings/0001831283-22-000061.md) | [109](/filings/0001831283-22-000075.md) | [228](/filings/0001831283-23-000041.md) | [140](/filings/0001831283-23-000081.md) | [134](/filings/0001831283-23-000110.md) | [78.9](/filings/0001831283-23-000126.md) | [79.2](/filings/0001831283-23-000126.md) | [102](/filings/0001831283-23-000081.md) | [104](/filings/0001831283-23-000110.md) | [103](/filings/0001831283-23-000126.md) |
| Current assets | $m | [277](/filings/0001831283-22-000014.md) | not reported | not reported | [121](/filings/0001193125-22-005640.md) | [400](/filings/0001831283-23-000041.md) | [386](/filings/0001831283-22-000042.md) | [344](/filings/0001831283-22-000061.md) | [324](/filings/0001831283-22-000075.md) | [313](/filings/0001831283-23-000126.md) | [296](/filings/0001831283-23-000081.md) | [273](/filings/0001831283-23-000110.md) | [258](/filings/0001831283-23-000126.md) |
| Total assets | $m | [279](/filings/0001831283-22-000014.md) | not reported | not reported | [142](/filings/0001193125-22-005640.md) | [426](/filings/0001831283-23-000041.md) | [413](/filings/0001831283-22-000042.md) | [372](/filings/0001831283-22-000061.md) | [352](/filings/0001831283-22-000075.md) | [320](/filings/0001831283-23-000126.md) | [303](/filings/0001831283-23-000081.md) | [279](/filings/0001831283-23-000110.md) | [263](/filings/0001831283-23-000126.md) |
| Current liabilities | $m | [6.2](/filings/0001831283-22-000014.md) | not reported | not reported | [22.3](/filings/0001193125-22-005640.md) | [15.1](/filings/0001831283-23-000041.md) | [25.2](/filings/0001831283-22-000042.md) | [21.7](/filings/0001831283-22-000061.md) | [22.0](/filings/0001831283-22-000075.md) | [23.6](/filings/0001831283-23-000126.md) | [25.9](/filings/0001831283-23-000081.md) | [21.6](/filings/0001831283-23-000110.md) | [25.6](/filings/0001831283-23-000126.md) |
| Total liabilities | $m | [27.6](/filings/0001831283-22-000014.md) | not reported | not reported | [42.3](/filings/0001193125-22-005640.md) | [39.0](/filings/0001831283-23-000041.md) | [48.7](/filings/0001831283-22-000042.md) | [45.6](/filings/0001831283-22-000061.md) | [45.2](/filings/0001831283-22-000075.md) | [26.3](/filings/0001831283-23-000126.md) | [28.2](/filings/0001831283-23-000081.md) | [23.3](/filings/0001831283-23-000110.md) | [26.8](/filings/0001831283-23-000126.md) |
| Shareholders' equity | $m | [(133)](/filings/0001831283-22-000014.md) | [(149)](/filings/0001831283-22-000075.md) | [(247)](/filings/0001831283-22-000075.md) | [(297)](/filings/0001193125-22-005640.md) | [354](/filings/0001831283-23-000041.md) | [331](/filings/0001831283-22-000042.md) | [292](/filings/0001831283-22-000061.md) | [273](/filings/0001831283-22-000075.md) | [260](/filings/0001831283-23-000126.md) | [241](/filings/0001831283-23-000081.md) | [222](/filings/0001831283-23-000110.md) | [202](/filings/0001831283-23-000126.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | period not labelled (2020-12-31) | period not labelled (2021-03-31) | period not labelled (2021-06-30) | Q3 FY2021 (2021-09-30) | Q4 FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(48.9) d](/filings/0001831283-22-000014.md) | [(1.9)](/filings/0001831283-22-000042.md) | [(92.9) d](/filings/0001831283-22-000061.md) | [(38.8) d](/filings/0001831283-22-000075.md) | [(30.4) d](/filings/0001831283-23-000041.md) | [(13.1)](/filings/0001831283-23-000081.md) | [(39.4) d](/filings/0001831283-23-000110.md) | [(16.0) d](/filings/0001831283-23-000126.md) | [(30.7) d](/filings/0001831283-23-000041.md) | [(17.6)](/filings/0001831283-23-000081.md) | [(19.3) d](/filings/0001831283-23-000110.md) | [(15.9) d](/filings/0001831283-23-000126.md) |
| Capital expenditure | $m | [0.6 d](/filings/0001831283-22-000014.md) | [0.0](/filings/0001831283-22-000042.md) | [0.0 d](/filings/0001831283-22-000061.md) | [0.1 d](/filings/0001831283-22-000075.md) | [0.8 d](/filings/0001831283-23-000041.md) | [0.3](/filings/0001831283-23-000081.md) | [0.3 d](/filings/0001831283-23-000110.md) | [0.9 d](/filings/0001831283-23-000126.md) | [0.2 d](/filings/0001831283-23-000041.md) | [0.0](/filings/0001831283-23-000081.md) | [0.1 d](/filings/0001831283-23-000110.md) | [0.2 d](/filings/0001831283-23-000126.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2021-03-31) | period not labelled (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [20.5](/filings/0001831283-22-000042.md) | [20.5](/filings/0001831283-22-000061.md) | [20.7](/filings/0001831283-22-000075.md) | [107](/filings/0001831283-23-000081.md) | [108](/filings/0001831283-23-000110.md) | [108](/filings/0001831283-23-000126.md) | [107](/filings/0001831283-23-000081.md) | [107](/filings/0001831283-23-000110.md) | [107](/filings/0001831283-23-000126.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 108,062,638 at 2023-11-09, from the cover of the [10-Q filed 2023-11-13](/filings/0001831283-23-000126.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.